MP BIOMEDICALS AND A*STAR CO-DEVELOP RAPID ANTIBODY POINT-OF-CARE TEST KIT FOR SARS-COV-2
SINGAPORE – MP Biomedicals Asia Pacific Pte Ltd, a diagnostic corporation which has been operating for over 30 years focusing on various infectious disease testing development and manufacturing, today announced the successful development of a rapid antibody test kit for COVID-19, in collaboration with the Agency for Science, Technology and Research (A*STAR). Named as the ASSURE® SARS-CoV-2 IgG/IgM rapid test, or ASSURE® in short, the test kit detects antibodies produced by the human immune system in response to exposure to SARS-CoV-2. It produces accurate results in as little as 15 minutes, and employs a lateral flow format similar to those used in home pregnancy tests. ASSURE® was developed and manufactured in Singapore. It can be deployed at or near the point of patient care, and has been distributed to regions such as Europe, Africa and South America. MP Biomedicals intends to file for Emergency Use Authorization (EUA) from the US FDA for this product as well.
SINGAPORE TO ADVANCE COVID-19 RESEARCH COLLABORATION WITH ASEAN AND STRENGTHEN REGIONAL CAPABILITIES TO COMBAT PANDEMICS
Under Singapore’s chairmanship of the ASEAN Ministerial Meeting on Science, Technology and Innovation, and the ASEAN Committee on Science, Technology and Innovation, ASEAN had seen stronger Science, Technology and Innovation (STI) collaboration, notably in intra-ASEAN capabilities to combat COVID-19 and future pandemics.
Translating R&D Into COVID-19 Kits: DxD Hub and Local Medtech Firms Ramp Up Singapore’s Testing Capability
A year has passed since the first case of COVID-19 was reported in Singapore. Ensuring a strong testing capability continues to be one of the nation’s key strategies to contain the spread of the stealthy virus, as large-scale testing allows for the early detection and isolation of cases before they infect others.
From Lab to Market: Putting Diagnostics Innovations on the Fast Track
The Diagnostics Development (DxD) Hub accelerates technology translation from lab to market, to improve healthcare and develop a robust diagnostic devices ecosystem in Singapore.
PUBLIC-PRIVATE COLLABORATION LEADS TO FINGER-PRICK ANTIBODY TEST KIT FOR COVID-19 THAT DELIVERS RESULTS IN 15 MINUTES
A test kit that can accurately identify SARS-CoV-2 antibodies in 15 minutes and employs a lateral flow format, similar to those used in home pregnancy tests, has been co-developed between A*STAR and diagnostics company MP Biomedicals.
A*STAR & PARTNERS ROLL OUT RESOLUTE 2.0 TEST AND AUTOMATED LAB SYSTEM RAVE THAT UPS TEST DELIVERY THROUGHPUT BY FOUR TIMES
DSO National Laboratories and A*STAR's Diagnostics Development (DxD) Hub have jointly developed RESOLUTE 2.0, a breakthrough Direct-Polymerase Chain Reaction (PCR) diagnostic test kit for COVID-19. This initiative was part of a strategic partnership between DSO and A*STAR that was inked earlier this year to tighten the defence-civilian research nexus.
